#United States #New York #Securities Fraud #Levi Korsinsky #BioAge Labs

Overview

Levi & Korsinsky LLP recently issued a notification to investors of BioAge Labs, Inc. regarding a pending class action lawsuit related to alleged securities fraud. The case highlights serious concerns that surfaced following the company's business decisions and communication concerning its lead product candidate, azelaprag.

Class Action Objective

This lawsuit seeks to recover losses on behalf of shareholders adversely affected by the supposed misconduct. Specifically, it targets individuals who purchased shares connected to the company’s initial public offering (IPO) around September 26, 2024. Investors are urged to act quickly, as they must apply as lead plaintiffs by March 10, 2025, if they wish to take on a significant role in the case.

Case Details

The impetus for the class action arose on December 6, 2024, when BioAge announced it would discontinue its ongoing STRIDES Phase 2 trial for azelaprag. The reason given was concerning safety issues linked to elevated liver transaminase levels in trial participants. This revelation came as a considerable shock, notably since, just three months prior, the company had touted the drug's potential benefits for patients undergoing obesity therapy. The immediate aftermath of the announcement saw a drastic plunge in BioAge’s stock price—from $20.09 per share to just $4.65 the next day, underscoring the significant financial impact on its investors.

Next Steps for Affected Investors

If you have experienced a loss through your investment in BioAge during the relevant period, it is essential to account for the March 10 deadline to apply as a lead plaintiff. Nonetheless, it is worth noting that participation in potential recovery does not necessitate serving in that role. As a class member, you may be eligible for compensation while incurring no out-of-pocket costs.

The Levi & Korsinsky Advantage

Levi & Korsinsky has carved out a solid reputation over the past two decades for representing investors in complex securities litigation. Their track record includes securing hundreds of millions of dollars for harmed shareholders, demonstrating their capability in handling high-stakes cases. Furthermore, they have consistently ranked among the top securities litigation firms in the United States, as indicated by ISS Securities Class Action Services.

How to Proceed

Investors looking for guidance can reach out to Levi & Korsinsky directly. Joseph E. Levi, a leading attorney at the firm, can be contacted via email or phone to discuss the specifics of the lawsuit and how to proceed with claims. With a dedicated team and a wealth of experience, they ensure that investors are adequately represented and supported throughout the litigation process.

In summary, if you have been impacted by the situation at BioAge Labs, taking timely action could pave the way for recovery opportunities. By understanding the specifics of this class action and engaging with experienced legal counsel, you are making a proactive move toward protecting your financial interests.

Contact Information

For more details, Benjamin E. Levi, Esq. is available via email at [email protected] or by phone at (212) 363-7500. More information can also be found on their website at www.zlk.com.